Category: RenalSyndicate content

Renal

Hypertension: Docs turn on renal denervation | MassDevice.com On Call

April 10, 2014 by Arezu Sarvestani

U.S. and E.U. cardiologists call for a hard check on global sales of renal denervation technology in the wake of Medtronic's disappointing SYMPLICITY HTN-3 study.

MassDevice.com On Call

MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.

ACC 2014: Conflicts in renal denervation, competition in valves

April 3, 2014 by Arezu Sarvestani

More results from Medtronic's hypertension studies continue to muddle the outlook for renal denervation as medtech titans vie for prime listing for their transcatheter valves.

fired/hired

The American College of Cardiology's annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic's (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ACC 2014: Medtronic details Symplicity renal denervation data

March 29, 2014 by Ingrid Mezo

Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said today at the American College of Cardiology's annual conference.

YYmeta

Medtronic (NYSE:MDT) revealed the details today of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

Hypertension: Cordis lands Euro approval for Renlane renal denervation

February 21, 2014 by Arezu Sarvestani

Johnson & Johnson subsidiary Cordis Corp. wins European CE Mark approval for its Renlane renal denervation system for treating patients with resistant hypertension.

Hypertension: Cordis lands Euro approval for Renlane renal denervation

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

NxStage launches dialysis patient outreach program

February 11, 2014 by Chris Walker

NxStage Medical campaigns to increase awareness of home hemodialysis with the NxStage System One.

NxStage begins patient outreach program

NxStage Medical (NSDQ:NXTM) launched a new patient outreach program called NxStage Plus One, through which it hopes to increase awareness of home hemodialysis with the NxStage System One.

Hypertension: ReCor charges ahead with ultrasound renal denervation

January 28, 2014 by Arezu Sarvestani

The recent chill in renal denervation hasn't slowed down ReCor Medical, which plans to charge forward with its ultrasound-based Paradise system for treatment of hypertension.

Hypertension: ReCor charges ahead with ultrasound renal denervation

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Analysts warn of deeper impact of Medtronic's renal denervation miss | MassDevice.com On Call

January 27, 2014 by Arezu Sarvestani

Analysts warn that medtech companies may become increasingly cautious toward "risky" bets after Medtronic's near billion-dollar gamble on renal denervation was derailed by a flopped clinical trial.

MassDevice.com On Call

MASSDEVICE ON CALL — Medtech titan Medtronic (NYSE:MDT) took a risk when it bet nearly $1 billion on renal denervation pioneer Ardian years before its flagship device was slated to hit the U.S. market, and the recent foofaraw over the company's missed clinical trial may have a cooling effect on other device companies, analysts warned.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp